Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Ruzzo, E
The vast majority of research is being generated from one or two individual institutions in Europe
Preclinical research literature on BPC-157 spans a broad range of connective-tissue and repair models
Reduces Pro-Inflammatory Cytokines KPV has been shown in laboratory and animal studies to reduce inflammatory messengers including: TNF- (Tumor Necrosis Factor-alpha) IL-1 (Interleukin-1 beta) IL-6 (Interleukin-6) NF-B activation These inflammatory molecules are elevated in numerous chronic diseases including: Autoimmune conditions Inflammatory bowel disease Arthritis Chronic skin disorders Metabolic disease By lowering these inflammatory signals, KPV may help reduce tissue damage and chronic inflammation
It is important to note that all current evidence derives from in vitro cellular models and in vivo animal studies, and no human clinical trials have been conducted as of February 2026
